The binding of CCL18 to its receptor PITPNM3 recruits macrophages in human breast cancer model with the collaboration of CSF2 mediators.17 An important player in the recruitment of monocytes to the tumor, is considered CCL2-CCR2 axis that has been proposed as a new therapeutic target.18 There is controversial debate about the exact origin of CCL2 within tumor. This evidence concerns the gene PITPNM3 and neoplasm.